{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:20:37Z","timestamp":1789870837124,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jocn.2018.01.017","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T19:38:08Z","timestamp":1517513888000},"page":"281-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study"],"prefix":"10.1016","volume":"50","author":[{"given":"Chun-Yu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2018.01.017_b0005","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2018.01.017_b0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jns.2009.05.006","article-title":"Diabetes mellitus and drug-induced Parkinsonism: a case-control study","volume":"284","author":"Ma","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2018.01.017_b0015","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson's disease in Denmark","volume":"34","author":"Schernhammer","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2018.01.017_b0020","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson\u2019s disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2018.01.017_b0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/dc11-1511","article-title":"Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications","volume":"35","author":"Sun","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jocn.2018.01.017_b0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.parkreldis.2005.09.004","article-title":"Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk","volume":"12","author":"Powers","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0035","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","article-title":"Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease","volume":"69","author":"Simon","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.017_b0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2009.02.013","article-title":"Diabetes preceding Parkinson\u2019s disease onset. A case-control study","volume":"15","author":"D'Amelio","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2010.03.002","article-title":"Case-control study of risk of Parkinson\u2019s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan","volume":"293","author":"Miyake","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2018.01.017_b0050","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/mds.23855","article-title":"Obesity, diabetes, and risk of Parkinson's disease","volume":"26","author":"Palacios","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0055","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/S0004-282X2004000500008","article-title":"Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine","volume":"62","author":"Fabiani","year":"2004","journal-title":"Arq NeuroPsiquiatr"},{"issue":"Suppl 8","key":"10.1016\/j.jocn.2018.01.017_b0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/03331024880080S804","article-title":"Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial","volume":"8","author":"Martinez-Lage","year":"1988","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jocn.2018.01.017_b0065","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial","volume":"271","author":"Lepcha","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jocn.2018.01.017_b0070","unstructured":"Melo-Souza SE. Flunarizina, parkinsonismo e depress\u00e3o. XI Congresso Brasileiro de Neurologia (Resumos). Goi\u00e2nia, Brasil; 1984."},{"key":"10.1016\/j.jocn.2018.01.017_b0075","first-page":"47","article-title":"Parkinson-like side effects during prolonged treatment with flunarizine","volume":"2","author":"Di Rosa","year":"1987","journal-title":"Funct Neurol"},{"key":"10.1016\/j.jocn.2018.01.017_b0080","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/WNL.37.5.881","article-title":"Flunarizine- and cinnarizine-induced extrapyramidal reactions","volume":"37","author":"Micheli","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2018.01.017_b0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/bmj.297.6650.722","article-title":"Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine","volume":"297","author":"Capella","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2018.01.017_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mds.870040205","article-title":"Movement disorders and depression due to flunarizine and cinnarizine","volume":"4","author":"Micheli","year":"1989","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","article-title":"A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism","volume":"12","author":"Negrotti","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.parkreldis.2003.12.004","article-title":"Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis","volume":"10","author":"Teive","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0105","doi-asserted-by":"crossref","first-page":"e80176","DOI":"10.1371\/journal.pone.0080176","article-title":"The prevalence and characteristics of metabolic syndrome in patients with vertigo","volume":"8","author":"Yamanaka","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2018.01.017_b0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/00016488809125148","article-title":"Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study","volume":"460","author":"Elbaz","year":"1988","journal-title":"Acta Otolaryngol Suppl"},{"key":"10.1016\/j.jocn.2018.01.017_b0115","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/00016480310001475","article-title":"Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo","volume":"123","author":"Albera","year":"2003","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.jocn.2018.01.017_b0120","unstructured":"NHIRD. National Health Insurance Research Database, Taiwan. http:\/\/nhird.nhri.org.tw\/en\/index.htm, http:\/\/nhird.nhri.org.tw\/en\/Data_Subsets.html; 2015 [access 2015\/8\/13]."},{"key":"10.1016\/j.jocn.2018.01.017_b0125","unstructured":"Therneau T. A Package for Survival Analysis in S. version 2.38; 2015."},{"key":"10.1016\/j.jocn.2018.01.017_b0130","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2015"},{"key":"10.1016\/j.jocn.2018.01.017_b0135","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(86)91223-7","article-title":"Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine","volume":"1","author":"Chouza","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2018.01.017_b0140","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/j.1552-4604.1988.tb03183.x","article-title":"Flunarizine-induced parkinsonism in the elderly","volume":"28","author":"Benvenuti","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jocn.2018.01.017_b0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(92)91112-R","article-title":"Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons","volume":"590","author":"Takada","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.jocn.2018.01.017_b0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(91)90526-V","article-title":"Interaction of flunarizine with dopamine D2 and D1 receptors","volume":"197","author":"Ambrosio","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jocn.2018.01.017_b0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-4943(91)90049-V","article-title":"Calcium antagonist flunarizine hydrochloride affects striatal D2 dopamine receptors in the young adult and aged rat brain","volume":"13","author":"Asanuma","year":"1991","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jocn.2018.01.017_b0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Brucke","year":"1995","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jocn.2018.01.017_b0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0026-895X(25)09898-0","article-title":"Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism","volume":"45","author":"Veitch","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jocn.2018.01.017_b0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cnr.2004.09.012","article-title":"Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status","volume":"4","author":"Warsh","year":"2004","journal-title":"Clin Neurosci Res"},{"key":"10.1016\/j.jocn.2018.01.017_b0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.20479","article-title":"Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data","volume":"20","author":"Swarztrauber","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2018.01.017_b0180","unstructured":"Rothman KJ. Dealing with biases. Epidemiology, An Introduction. 2nd ed. New York: Oxford University Press; 2012. p. 129\u201330."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817309451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586817309451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T12:21:26Z","timestamp":1751286086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586817309451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":36,"alternative-id":["S0967586817309451"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.017","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: A nested case-control study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2018.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}